Inotuzumab Ozogamicin is a special medicine that helps treat young people with a type of blood cancer. This cancer might come back after treatment (relapsed) or not respond to treatment (refractory). This medicine works like a guided missile. It uses an antibody called inotuzumab that finds cancer cells with a tag called CD22 and delivers the drug ozogamicin to kill them.
This study checks how well inotuzumab ozogamicin works and how safe it is. There are two groups, or "cohorts," in the study:
- Cohort 1: Patients get the medicine once a week for three weeks in a 28-day cycle, up to six cycles.
- Cohort 2: Patients get different drugs along with inotuzumab ozogamicin over a 42-day cycle, up to two cycles.
Key points for you to consider:
- Study Length: Up to 6 months for some patients, with follow-ups for several years.
- Visits Needed: Regular hospital visits for treatment and tests.
- Potential Risks: Possible side effects include liver problems and other drug-related reactions.
Participants will have tests like blood samples and bone marrow checks. After treatment, patients will be checked regularly to see how they are doing.
How understandable was the trial content above?
Hard to understand
Easy to understand